{'fraction_non_alphanumeric': 0.03287671232876712, 'fraction_numerical': 0.0182648401826484, 'mean_word_length': 5.122905027932961, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Elbasvir/grazoprevir treatment in a hemodialysis patient with hepatitis C Virus Genotype 2a Infection, not responded to sofosbuvir/daclatasvir combination therapy

Since 2017, direct-acting antivirals (DAAs) are the first-line treatment for patients with chronic hepatitis C virus (HCV) infection. In hemodialysis (HD) patients, however, a small percentage of patients failed to respond, and the data for the treatment of DAAs for such patients with HCV are lacking. Herein, we report a 57-year-old Libyan female patient on regular HD therapy for 18 years who did not achieved HCV clearance 12 weeks after the treatment with sofosbuvir/daclatasvir. Later, she was treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks and achieved a sustained virological response at the end of the treatment (12 weeks) and 12 months after the end of the treatment. No obvious side effects were reported during the treatment. Thus, EBR/GZR was effective and safe in this hemodialyzed patient with HCV genotype 2b infection who was failed to respond to12 week-treatment with sofosbuvir/daclatasvir combination.